WCLC 2025 - Posters & ePosters-P3.12.55 Efficacy of Vebreltinib in Advanced NSCLC Patients With MET Exon 14-Skipping: Post-Hoc Analysis of KUNPENG Study

P3.12.55 Efficacy of Vebreltinib in Advanced NSCLC Patients With MET Exon 14-Skipping: Post-Hoc Analysis of KUNPENG Study

Back to course

Pdf Summary

The post-hoc analysis of the phase II KUNPENG study evaluates the efficacy of vebreltinib, a selective c-MET inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations. The open-label, multicenter study enrolled 52 patients in Cohort 1, with 46 patients constituting the Per-Protocol Set (PPS): 21 treatment-naïve and 25 pretreated. Patients received 200mg vebreltinib twice daily until disease progression, unacceptable toxicity, or withdrawal.<br /><br />Key efficacy outcomes assessed by a blinded independent review committee include an objective response rate (ORR) of 80.4% (95% CI: 69.0-91.9%) and a disease control rate (DCR) of 97.8% (95% CI: 93.6-100%). The median duration of response (DoR) was 19.1 months, median progression-free survival (PFS) was 17.5 months, and median overall survival (OS) was 22.5 months, with a 3-year OS rate of 39.7%. Subgroup analysis showed superior outcomes in treatment-naïve patients with an ORR of 85.7%, median PFS of 25.8 months, and median OS of 44.3 months. Patients with baseline brain metastases (n=5) demonstrated an ORR of 100%, with median PFS of 6.4 months and OS of 17.9 months, indicating vebreltinib’s activity across these patient subsets.<br /><br />The treatment was generally well tolerated, and the durable tumor responses suggest vebreltinib provides significant clinical benefit, particularly in treatment-naïve patients, potentially translating to long-term survival advantages. The study supports vebreltinib as a promising targeted therapy for MET exon 14-skipping NSCLC. A Phase IIIb trial is underway to further validate these findings. This research, sponsored by Avistone Biotechnology, underscores the importance of molecularly targeted therapies in managing advanced NSCLC with specific genetic alterations.

Asset Subtitle

Jin-Ji Yang

Meta Tag

Speaker Jin-Ji Yang

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

vebreltinib

c-MET inhibitor

non-small cell lung cancer

NSCLC

MET exon 14-skipping mutation

phase II KUNPENG study

objective response rate

progression-free survival

overall survival

targeted therapy